CHINA HI-TECH(600730)

Search documents
中国高科(600730) - 中国高科集团股份有限公司独立董事工作制度(2025年修订)
2025-04-29 09:49
中国高科集团股份有限公司 独立董事工作制度 (2025 年 4 月) 第一章 总 则 第一条 为进一步提高中国高科集团股份有限公司(以下简称"公司")治理 水平,切实保护全体股东特别是中小股东的利益,促进公司规范运作,根据中国 证券监督管理委员会《上市公司独立董事管理办法》(以下简称《管理办法》)、 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关法律、法 规、规范性文件及《中国高科集团股份有限公司公司章程》(以下简称《公司章 程》)的相关规定,制定本工作制度。 第二条 独立董事是指不在公司担任除董事外的其他职务,并与公司及其主 要股东、实际控制人不存在直接或间接利害关系,或者其他可能影响其进行独立 客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务。独立董事应当按 照《管理办法》等相关法律法规及规范性文件和《公司章程》的规定,认真履行 职责,在董事会中发挥参与决策、监督制衡、专业咨询作用,维护公司整体利益, 保护中小股东合法权益。 第四条 独立董事应当独立履行职责,不受公司及其主要股东、实际控制人 等单位或者个人的影响。独立董事原则上最多在三家境内上市公司担任独立董事 ...
中国高科(600730) - 中国高科集团股份有限公司董事会议事规则(2025年修订)
2025-04-29 09:49
第一条 为了进一步规范中国高科集团股份有限公司(以下简称"本公司" 或"公司")董事会的议事方式和决策程序,促使董事和董事会有效地履行其职责, 提高董事会规范运作和科学决策水平,根据《中华人民共和国公司法》(以下简 称《公司法》)、《中华人民共和国证券法》、《上市公司治理准则》、《上海证券交 易所股票上市规则》和《中国高科集团股份有限公司章程》(以下简称《公司章 程》)等有关规定,结合本公司实际情况,制订本规则。 第二条 董事会是公司经营决策的常设机构,遵照《公司法》等有关法律法 规及《公司章程》的规定,履行职责。 第三条 董事会下设董事会办公室,处理董事会日常事务。证券事务代表保 管董事会印章。 中国高科集团股份有限公司 董事会议事规则 (2025 年 4 月) 第一章 总 则 第二章 董事会 (七)决定公司因《公司章程》第二十六条第(三)、(五)、(六)项规定的 情形收购本公司股份的事项; 1 (二)执行股东会的决议; (三)决定公司的经营计划和投资方案; (四)制订公司的利润分配方案和弥补亏损方案; (八)在股东会授权范围内,决定公司对外投资、收购出售资产、资产抵押、 对外担保事项、委托理财、关联交易、 ...
中国高科(600730) - 中国高科集团股份有限公司内部审计管理制度(2025年)
2025-04-29 09:49
中国高科集团股份有限公司 内部审计管理制度 (2025 年 4 月) 第一章 总 则 第一条 为加强中国高科集团股份有限公司(以下简称"公司")内部审计 工作,规范内部审计行为,保证内部审计质量,明确内部审计机构和内部审计人 员的责任,根据《中华人民共和国审计法》《中国内部审计准则》等法律法规和 《中国高科集团股份有限公司章程》(以下简称"公司章程")的有关规定,结合 公司实际情况,制定本制度。 第二条 公司及所属企业开展内部审计工作,适用本制度。 第三条 本制度所称内部审计,是一种独立、客观的确认和咨询活动,它通 过运用系统、规范的方法,审查和评价公司的业务活动、风险管理、内部控制、 财务信息的适当性和有效性,以促进公司完善治理、增加价值和实现目标。 第四条 内部审计部门和内部审计人员从事内部审计工作应当严格遵守有 关法律法规、本制度和内部审计职业规范,做到独立、客观、公正、保密。 内部审计部门和内部审计人员不得参与可能影响独立、客观履行审计职责的 工作,不得负责被审计单位的业务活动、内部控制和风险管理的决策与执行。 内部审计人员与被审计单位(人员)或者审计事项有利害关系的,应当回避。 第二章 内部审计机构 ...
中国高科(600730) - 中国高科关于取消监事会并修订《公司章程》部分条款的公告
2025-04-29 09:40
证券代码:600730 证券简称:中国高科 公告编号:临 2025-015 中国高科集团股份有限公司 关于取消监事会并修订《公司章程》部分条款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 为全面贯彻落实最新法律法规要求,进一步完善公司治理,根据《中华人民 共和国公司法》、《上市公司治理准则》、《上市公司章程指引》等法律、规范性文 件的最新规定,中国高科集团股份有限公司(以下简称"公司")于 2025 年 4 月 29 日召开第十届董事会第十三次会议、第十届监事会第十次会议审议通过了《关 于取消公司监事会的议案》,本议案尚需提交公司股东大会审议。自股东大会审 议通过之日起,公司将不再设置监事会,监事会的职权由董事会审计委员会行使, 公司原《中国高科监事会议事规则》等与监事或监事会有关的管理制度及其他管 理制度相关条款废止。 根据《中华人民共和国公司法》、《上市公司治理准则》、《上市公司章程指引》、 《上市公司独立董事管理办法》等法律、规范性文件的最新规定,公司召开第十 届董事会第十三次会议,审议通过了《关于修订<公司章 ...
2246家公司公布年报 234家业绩增幅翻倍
Zheng Quan Shi Bao Wang· 2025-04-21 02:33
Core Insights - As of April 21, 2024, 2,246 companies have released their annual reports, with 1,197 reporting a year-on-year increase in net profit, while 1,049 reported a decline [1] - A total of 1,341 companies saw an increase in operating revenue, whereas 904 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include 940 firms, while 648 companies saw declines in both metrics [1] - Notably, 234 companies achieved a net profit growth rate exceeding 100%, with Zhengdan Co., Ltd. leading at an impressive 11,949.39% increase [1] Company Performance Summary - Zhengdan Co., Ltd. (300641) reported earnings per share of 2.35 yuan, with a net profit of 1,189.89 million yuan, reflecting a year-on-year increase of 11,949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) reported earnings per share of 0.043 yuan, with a net profit of 62.99 million yuan, a significant increase of 3,704.04%, but a decline in operating revenue by 76.48% to 393.16 million yuan [1] - Siwei (688213) achieved earnings per share of 0.98 yuan, with a net profit of 39.27 million yuan, marking a 2,662.76% increase, and operating revenue of 596.81 million yuan, up 108.87% [1] - Other notable performers include Andis (600299) with a net profit of 120.43 million yuan (up 2,208.66%) and operating revenue of 1,553.43 million yuan (up 17.83%) [1] - Companies like Huabei Pharmaceutical (600812) and Jiangsu Suo (600746) also reported significant changes in their financial metrics, with varying trends in net profit and operating revenue [1][2]
《鸿蒙开物》:开启中国高科技可以抵达的新高度
Sou Hu Cai Jing· 2025-04-20 06:21
Core Insights - The history of HarmonyOS is characterized as a tragic and heroic narrative rather than a simple tale of heroism, emphasizing the collective effort and struggles of its creators [1] - HarmonyOS is presented as a shared achievement, not solely belonging to Huawei or China, but as a collective endeavor that resonates with a broader audience [1] - The book aims to provide an accessible and engaging account of the development of HarmonyOS, focusing on real stories behind the technology [1][2] Group 1 - The project involves in-depth interviews with around 300 key figures across six core technology products, aiming to comprehensively document the journey and stories behind them [2] - Initial excitement about completing the six books by 2024 was met with unforeseen challenges, leading to delays in writing and publishing [2][4] - The first book, "The Rise of Euler," was published in 2023, with "Harmony" being the second book scheduled for 2025 [2] Group 2 - The extensive writing process has led to a deeper understanding of Huawei, revealing its transformation over the past six years amid technological challenges [4][5] - The narrative of Huawei's journey is seen as one of the most significant stories of the era, deserving of continuous exploration and analysis [5] - The book encapsulates the struggles and triumphs of ordinary individuals in the tech industry, highlighting their courage and determination in overcoming failures [6]
1695家公司公布年报 180家业绩增幅翻倍
Zheng Quan Shi Bao Wang· 2025-04-17 02:36
Core Insights - As of April 17, 1695 companies have released their 2024 annual reports, with 947 reporting a year-on-year increase in net profit, while 748 reported a decline [1] - 1026 companies saw a year-on-year increase in operating revenue, whereas 669 experienced a decrease [1] - 750 companies reported simultaneous growth in both net profit and operating revenue, while 472 companies saw declines in both metrics [1] - A total of 180 companies achieved a doubling of their performance, with Zhengdan Co. leading with a staggering net profit growth of 11949.39% [1] Company Performance Summary - Zhengdan Co. (300641) reported earnings per share of 2.35 yuan, net profit of 118.99 million yuan, a year-on-year increase of 11949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) had earnings per share of 0.043 yuan, net profit of 6.30 million yuan, a year-on-year increase of 3704.04%, but a significant decline in operating revenue by 76.48% to 393.16 million yuan [1] - North China Pharmaceutical (600812) reported earnings per share of 0.074 yuan, net profit of 12.70 million yuan, a year-on-year increase of 2496.80%, with operating revenue of 986.96 million yuan, down 2.48% [1] - Andisoo (600299) achieved earnings per share of 0.45 yuan, net profit of 120.43 million yuan, a year-on-year increase of 2208.66%, and operating revenue of 1.55 billion yuan, up 17.83% [1] - Other notable companies include Jiangsu Suopu (600746) with a net profit increase of 1029.62% and operating revenue growth of 18.43% [1] Additional Company Insights - Baoli Tianheng (688506) reported an impressive earnings per share of 9.25 yuan, net profit of 370.75 million yuan, and a remarkable year-on-year increase of 936.31% in net profit, with operating revenue of 582.27 million yuan [2] - Muyuan Foods (002714) achieved earnings per share of 3.30 yuan, net profit of 1.79 billion yuan, a year-on-year increase of 519.42%, and operating revenue of 13.79 billion yuan, up 24.43% [2] - Other companies like Xizi Clean Energy (002534) and Zhongchuan Defense (600685) reported varying performance metrics, with Xizi Clean Energy showing a decline in operating revenue by 20.33% [2]
1567家公司公布年报 158家业绩增幅翻倍
Zheng Quan Shi Bao Wang· 2025-04-15 02:53
Core Insights - As of April 15, 2024, 1,567 companies have released their annual reports, with 874 reporting a year-on-year increase in net profit, while 693 reported a decline [1] - A total of 942 companies saw an increase in operating revenue, whereas 625 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include Andisoo, among 686 others, while 437 companies saw declines in both metrics [1] Financial Performance Highlights - Guangxi Energy reported the highest net profit growth at 3,704.04%, with a net profit of 62.99 million and operating revenue of 393.16 million, which decreased by 76.48% [1] - North China Pharmaceutical achieved a net profit increase of 2,496.80%, with a net profit of 126.99 million and operating revenue of 986.96 million, down by 2.48% [1] - Andisoo's net profit rose by 2,208.66% to 1,204.33 million, with operating revenue increasing by 17.83% to 1,553.43 million [1] - Other notable performers include: - Shengyi Electronics: net profit up 1,428.23% to 331.97 million, operating revenue up 43.19% to 468.66 million [1] - Hualin Securities: net profit up 1,014.54% to 353.15 million, operating revenue up 41.35% to 143.48 million [1] Additional Company Insights - Companies with significant net profit increases also include: - Microelectronics: net profit up 815.36% to 5.21 million, operating revenue up 25.51% to 41.32 million [1] - Zhengzhou Coal: net profit up 783.88% to 282.66 million, operating revenue down by 2.74% to 420.49 million [1] - The report highlights a mix of performance across various sectors, indicating diverse trends in profitability and revenue growth among the listed companies [1][2]
中国高科(600730) - 中国高科2024年年度股东大会的法律意见书
2025-04-08 11:45
为出具本法律意见书,本所律师审查了公司提供的以下文件,包括但不限于: 1. 经公司 2023 年年度股东大会审议通过的《公司章程》; 2. 公司于 2025 年 3 月 19 日刊登于巨潮资讯网及上海证券交易所网站的《中 国高科集团股份有限公司第十届董事会第十二次会议决议公告》《中国高科集团股 份有限公司第十届监事会第九次会议决议公告》; 3. 公司于 2025 年 3 月 19 日刊登于巨潮资讯网及上海证券交易所网站的《中 国高科集团股份有限公司关于召开 2024 年年度股东大会的通知》(以下简称《股 东大会通知》); 4. 公司本次股东大会股权登记日的股东名册; 5. 出席现场会议的股东的到会登记记录及凭证资料; 北京市金杜律师事务所 关于中国高科集团股份有限公司 2024 年年度股东大会 的法律意见书 致:中国高科集团股份有限公司 北京市金杜律师事务所(以下简称本所)接受中国高科集团股份有限公司(以 下简称公司)委托,根据《中华人民共和国证券法》(以下简称《证券法》)、《中 华人民共和国公司法》(以下简称《公司法》)、中国证券监督管理委员会《上市公 司股东会规则(2025 年修订)》(以下简称《股东会规 ...
中国高科(600730) - 中国高科2024年年度股东大会决议公告
2025-04-08 11:45
证券代码:600730 证券简称:中国高科 公告编号:临 2025-012 中国高科集团股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 | 1、出席会议的股东和代理人人数 | 262 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数(股) | 139,134,149 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 23.7164 | | 份总数的比例(%) | | (四) 表决方式是否符合《公司法》及《公司章程》的规定,大会主持情况等。 本次会议由公司董事会召集,现场会议由董事长聂志强先生主持,会议采取 现场投票与网络投票相结合的方式召开。本次会议的召集和召开程序、表决方式 符合《公司法》等有关法律、法规和《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事 9 人,出席 9 人; 2、 公司在任监事 5 人,出席 4 人,监事胡俊涛先生因工作原因请假,未出 席本次股东大会; 重要内容提示: 本次会议 ...